Cargando…

Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice

BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chia-Chih, Yu, Huang-Ping, Yang, Shih-Chun, Alalaiwe, Ahmed, Dai, You-Shan, Liu, Fu-Chao, Fang, Jia-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885212/
https://www.ncbi.nlm.nih.gov/pubmed/33588861
http://dx.doi.org/10.1186/s12951-021-00789-5
_version_ 1783651560035713024
author Liao, Chia-Chih
Yu, Huang-Ping
Yang, Shih-Chun
Alalaiwe, Ahmed
Dai, You-Shan
Liu, Fu-Chao
Fang, Jia-You
author_facet Liao, Chia-Chih
Yu, Huang-Ping
Yang, Shih-Chun
Alalaiwe, Ahmed
Dai, You-Shan
Liu, Fu-Chao
Fang, Jia-You
author_sort Liao, Chia-Chih
collection PubMed
description BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with antibacterial and anti-inflammatory effects may be beneficial in treating bacteremia. This study aimed to develop nanostructured lipid carriers (NLCs) loaded with ciprofloxacin and rolipram that exert a combination of anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-inflammatory effects. Retinol was incorporated into the nanoparticles to transport retinol-binding protein 4 (RBP4) to the kidneys, which abundantly express RBP receptors. The NLCs were fabricated by high-shear homogenization and sonication, and neutrophils were used as a model to assess their anti-inflammatory effects. Mice were injected with MRSA to establish a model of bacteremia with organ injury. RESULTS: The mean nanoparticle size and zeta potential of the NLCs were 171 nm and − 39 mV, respectively. Ciprofloxacin (0.05%, w/v) and rolipram (0.02%) achieved encapsulation percentages of 88% and 96%, respectively, in the nanosystems. The minimum bactericidal concentration of free ciprofloxacin against MRSA increased from 1.95 to 15.63 µg/ml when combined with rolipram, indicating a possible drug-drug interaction that reduced the antibacterial effect. Nanoparticle inclusion promoted the anti-MRSA activity of ciprofloxacin according to time-kill curves. The NLCs were found to be largely internalized into neutrophils and exhibited superior superoxide anion inhibition than free drugs. Retinol incorporation into the nanocarriers facilitated their efficient targeting to the kidneys. The NLCs significantly mitigated MRSA burden and elastase distribution in the organs of MRSA-infected animals, and the greatest inhibition was observed in the kidneys. Bacterial clearance and neutrophil infiltration suppression attenuated the bacteremia-induced cytokine overexpression, leading to an improvement in the survival rate from 22% to 67%. CONCLUSIONS: The dual role of our NLCs endowed them with greater efficacy in treating MRSA bacteremia than that of free drugs. [Image: see text]
format Online
Article
Text
id pubmed-7885212
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78852122021-02-17 Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice Liao, Chia-Chih Yu, Huang-Ping Yang, Shih-Chun Alalaiwe, Ahmed Dai, You-Shan Liu, Fu-Chao Fang, Jia-You J Nanobiotechnology Research BACKGROUND: Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure. Kidneys are one of the main organs affected by bacteremia. Combination therapies with antibacterial and anti-inflammatory effects may be beneficial in treating bacteremia. This study aimed to develop nanostructured lipid carriers (NLCs) loaded with ciprofloxacin and rolipram that exert a combination of anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-inflammatory effects. Retinol was incorporated into the nanoparticles to transport retinol-binding protein 4 (RBP4) to the kidneys, which abundantly express RBP receptors. The NLCs were fabricated by high-shear homogenization and sonication, and neutrophils were used as a model to assess their anti-inflammatory effects. Mice were injected with MRSA to establish a model of bacteremia with organ injury. RESULTS: The mean nanoparticle size and zeta potential of the NLCs were 171 nm and − 39 mV, respectively. Ciprofloxacin (0.05%, w/v) and rolipram (0.02%) achieved encapsulation percentages of 88% and 96%, respectively, in the nanosystems. The minimum bactericidal concentration of free ciprofloxacin against MRSA increased from 1.95 to 15.63 µg/ml when combined with rolipram, indicating a possible drug-drug interaction that reduced the antibacterial effect. Nanoparticle inclusion promoted the anti-MRSA activity of ciprofloxacin according to time-kill curves. The NLCs were found to be largely internalized into neutrophils and exhibited superior superoxide anion inhibition than free drugs. Retinol incorporation into the nanocarriers facilitated their efficient targeting to the kidneys. The NLCs significantly mitigated MRSA burden and elastase distribution in the organs of MRSA-infected animals, and the greatest inhibition was observed in the kidneys. Bacterial clearance and neutrophil infiltration suppression attenuated the bacteremia-induced cytokine overexpression, leading to an improvement in the survival rate from 22% to 67%. CONCLUSIONS: The dual role of our NLCs endowed them with greater efficacy in treating MRSA bacteremia than that of free drugs. [Image: see text] BioMed Central 2021-02-15 /pmc/articles/PMC7885212/ /pubmed/33588861 http://dx.doi.org/10.1186/s12951-021-00789-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liao, Chia-Chih
Yu, Huang-Ping
Yang, Shih-Chun
Alalaiwe, Ahmed
Dai, You-Shan
Liu, Fu-Chao
Fang, Jia-You
Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title_full Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title_fullStr Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title_full_unstemmed Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title_short Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
title_sort multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating mrsa bacteremia in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885212/
https://www.ncbi.nlm.nih.gov/pubmed/33588861
http://dx.doi.org/10.1186/s12951-021-00789-5
work_keys_str_mv AT liaochiachih multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT yuhuangping multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT yangshihchun multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT alalaiweahmed multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT daiyoushan multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT liufuchao multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice
AT fangjiayou multifunctionallipidbasednanocarrierswithantibacterialandantiinflammatoryactivitiesfortreatingmrsabacteremiainmice